Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia
- 26 May 2005
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 19 (8), 1416-1423
- https://doi.org/10.1038/sj.leu.2403809
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- WT1 as a Universal Marker for Minimal Residual Disease Detection and Quantification in Myeloid Leukemias and in Myelodysplastic SyndromeActa Haematologica, 2004
- WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients – results from a single‐centre studyBritish Journal of Haematology, 2004
- New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcriptsBlood, 2003
- Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patientsLeukemia, 2002
- Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometryLeukemia, 2002
- Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcriptsLeukemia, 2002
- Wilms' Tumor Gene Product WT1 Arrests Macrophage Differentiation of HL-60 Cells Through Its Zinc-Finger DomainBiochemical and Biophysical Research Communications, 1999
- Constitutive expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937 blocks parts of the differentiation programOncogene, 1998
- Wilms Tumor Gene Expression in Acute Myeloid LeukemiasLeukemia & Lymphoma, 1997
- Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locusCell, 1990